Objective: Recent reports have shown that endoplasmic reticulum (ER) stress is associated with cancer. However, the impacts of ER stress on the prognosis of lung cancer are unknown. Therefore, in this study, we sought to reveal the relationship between the expression of ER stress-related genes (ERO1L, PERK, ATF6 and IRE1) and the outcome of lung adenocarcinoma. Methods: One hundred and twenty-six patients with surgically resected lung adenocarcinomas were subjected to an ER stress-related mRNA expression analysis using quantitative RT-PCR. The following parameters were analyzed for all the study patients: age, sex, disease stage, smoking status, lymph node invasion (ly), vascular invasion (v), and EGFR mutation status. We assigned patients to either a high expression group (H group) or a low expression group (L group) according to the expression levels of ER stress-related genes. Results: High expressions of ER stress-related genes were observed in patients with lower stages of lung adenocarcinoma and minimal vascular invasion. A Kaplan-Meier analysis showed significant differences in recurrence-free survival (RFS) and overall survival between H group and L group. High IRE1 expression was an independent predictor of RFS among patients with lung adenocarcinoma (hazard ratio, 0.396; 95%confidence interval, 0.188 -0.834; P ¼ 0.015). Conclusions: IRE1 may be a useful biomarker to predict recurrence in surgically resected lung adenocarcinoma patients. The median progression free survival was 104 days. Adverse events were below Grade 2 in most cases. Over Grade 3 immune-related adverse events (irAEs) were interstitial pneumonia (IP): 5 cases, hyperglycemia: 2 cases and isolated ACTH deficiency: 1 case. Background: Nivolumab (NIVO) is a standard therapy in second line therapy of advanced/recurrent NSCLC, but due to the high progression disease rate and the pseudo-progression, appropriate judgment of treatment discontinuation is important. Patients and methods: In order to examine the proper use of NIVO, we analyzed the characteristics of exacerbated sites due to differences in overall response. NSCLC patients treated with NIVO at our hospital from January 2016 to November 2016 were analyzed. And the exacerbation site at the time of discontinuation was classified as "existing lesion" or "new lesion" by the overall response. Furthermore, for patients of stage IIIB (curative radiation impossible) and stage IV, exacerbating sites were classified into "primary lesion", "existing metastatic lesion", and "new lesion", and exaggeration patterns in each group were analyzed. Results: The characteristics of the 43 patients enrolled were as followings; median age, 66 years (range, 39-85 years), male/female¼31/12, PS 0/1/2¼0/35/8, Non-Sq/Sq¼32/ 11, EGFR mutation (yes/no/unknown) ¼9/29/5. The median number of treatment cycles was four (range, 1-21). The ORR was 16.3%. The median PFS was 1.87 months (95% CI, 1.6-2.2 months). For the 35 patients who had confirmed the exacerbation site at the time of discontinuation, comparison between the DCR and the PD group showed progression in more organs in the PD group (median number of the site: 2 vs. 3, p ¼ 0.023). Also, the PD group tended to have more lymphangitic carcinomatosis than the DCR group as new lesion. In the analysis of 24 patients of the stage IIIB and IV, in the DCR group, exacerbations not including "primary lesion" were 34%, which is a tendency to be higher than that of 16% of the PD group. Conclusion: In the DCR group, though exacerbations in existing metastatic lesions and newly developed lesions tended to be larger than in the PD group, the number of exacerbating organs tended to be small. . In addition, we studied the levels of ionized Zinc and Cadmium in the blood serum of the patients and rats, using Fluorescent Spectrophotometry (F96) and the unique correlation was found, namely: in all cases of prostate Cancer, Zinc consistence in blood serum was lower than norm, but Cadmium consistence was normal or at the lowest limit of the norm. In Prostate Adenoma, the blood plasma level of Zinc was at the lowest limit of norm and Cadmium level was normal. In the blood serum of healthy rats, the serum values of Zinc and Cadmium were within the norm. As the result of the study, we can conclude that MLT1 gene expression has certain screening value in early diagnosis of Prostate Cancer and the search for the target activator of MLT1gene can trigger the new era in the treatment of Prostate Cancer. The correlation between Zinc and cadmium is also interesting. It can also become a routine test in early diagnosis of Prostate Cancer and balancing their levels in the organism can become one of the strategic methodic recommendations in Prostate Cancer prevention. Background: Initial metastatic and/or invasive prostate cancers are difficult to cure completely because they easily and quickly change to CRPC without hormonal therapy. We examined initial D2 prostate cancer primarily treated with the GnRH antagonist Degarelix acetate.
How do you treat cancer patients who experienced lung injury during chemotherapy? Our staffs(n ¼ 52) answered as follows:Best supportive care only 10, 19.4%;Other chemotherapy regimen 33, 67.3%;Continue same regimen with steroids 14, 26.9%. Gap exists between pulmonologists and non-pulmonologists. We reviewed a consecutive series of 88 cancer patients who had lung injury during chemotherapy at our hospital during April 2002 and Sept 2016. Median age(range): 67(42-84). Male/Female:70/18. Cancer type: lung cancer 54, colon cancer 13, esophageal cancer 3, gastric cancer 3, renal cancer 4, breast cancer 1, prostate cancer 1, uterine sarcoma 1, leukemia 3, multiple myeloma 3, malignant lymphoma 1, neuroendocrine tumor 1. Pattern of lung injury: diffuse alveolar damage (DAD) 51, 58.0%; organizing pneumonia 32, 36.4%; hypersensitivity pneumonitis 2, 2.3%; capillary leak syndrome 2, 2.3%: nonspecific interstitial pneumonia 1, 1.1%. Severity of lung injury: Grade 1/2/3/4/5;7/8/21/1/51. 30 day mortality: total 27/88, 30.7%; lung cancer 23/54, 42.6%; DAD 25/51, 49.0%. Thirteen patients (14.8%) received chemotherapy after lung injury occurred, and two (15.4%) of them experienced lung injury again. Although we can treat some cancer patients with chemotherapy again, to predict the occurrence and severity of lung injury before chemotherapy is difficult. Background: Nivolumab (NIVO) is a standard therapy in second line therapy of advanced/recurrent NSCLC, but due to the high progression disease rate and the pseudo-progression, appropriate judgment of treatment discontinuation is important. Patients and methods: In order to examine the proper use of NIVO, we analyzed the characteristics of exacerbated sites due to differences in overall response. NSCLC patients treated with NIVO at our hospital from January 2016 to November 2016 were analyzed. And the exacerbation site at the time of discontinuation was classified as "existing lesion" or "new lesion" by the overall response. Furthermore, for patients of stage IIIB (curative radiation impossible) and stage IV, exacerbating sites were classified into "primary lesion", "existing metastatic lesion", and "new lesion", and exaggeration patterns in each group were analyzed. Results: The characteristics of the 43 patients enrolled were as followings; median age, 66 years (range, 39-85 years), male/female¼31/12, PS 0/1/2¼0/35/8, Non-Sq/Sq¼32/ 11, EGFR mutation (yes/no/unknown) ¼9/29/5. The median number of treatment cycles was four (range, 1-21). The ORR was 16.3%. The median PFS was 1.87 months (95% CI, 1.6-2.2 months). For the 35 patients who had confirmed the exacerbation site at the time of discontinuation, comparison between the DCR and the PD group showed progression in more organs in the PD group (median number of the site: 2 vs. 3, p ¼ 0.023). Also, the PD group tended to have more lymphangitic carcinomatosis than the DCR group as new lesion. In the analysis of 24 patients of the stage IIIB and IV, in the DCR group, exacerbations not including "primary lesion" were 34%, which is a tendency to be higher than that of 16% of the PD group. Conclusion: In the DCR group, though exacerbations in existing metastatic lesions and newly developed lesions tended to be larger than in the PD group, the number of exacerbating organs tended to be small. . In addition, we studied the levels of ionized Zinc and Cadmium in the blood serum of the patients and rats, using Fluorescent Spectrophotometry (F96) and the unique correlation was found, namely: in all cases of prostate Cancer, Zinc consistence in blood serum was lower than norm, but Cadmium consistence was normal or at the lowest limit of the norm. In Prostate Adenoma, the blood plasma level of Zinc was at the lowest limit of norm and Cadmium level was normal. In the blood serum of healthy rats, the serum values of Zinc and Cadmium were within the norm. As the result of the study, we can conclude that MLT1 gene expression has certain screening value in early diagnosis of Prostate Cancer and the search for the target activator of MLT1gene can trigger the new era in the treatment of Prostate Cancer. The correlation between Zinc and cadmium is also interesting. It can also become a routine test in early diagnosis of Prostate Cancer and balancing their levels in the organism can become one of the strategic methodic recommendations in Prostate Cancer prevention.
